Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biotechnology
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Shares of German drug discovery company Evotec leapt 20% to 10.33 euros this morning on the revelation that the USA’s Halozyme Therapeutics has submitted a non-binding proposal to acquire Evotec for 11.00 euros per share in cash, implying a fully-diluted equity value of around 2.0 billion euros ($2.12 billion). 15 November 2024
Biotechnology
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Grifols is set to acquire a minority stake in a US biopharmaceutical company based in San Francisco (California) specialized in the discovery and development of pre-clinical biotherapeutics. 7 July 2017
Pharmaceutical
The European Commission has sent three separate Statements of Objections to Germany’s Merck KGaA and its subsidiary Sigma-Aldrich, General Electric and Canon alleging they breached EU merger rules. 6 July 2017
Generics
Ireland-incorporated Endo International (Nasdaq: ENDP) has entered into a definitive agreement to sell Mexico City based Grupo Farmacéutico SOMAR to private equity firm Advent International. 5 July 2017
Pharmaceutical
The purchase of major pharma contract research organization Parexel was the largest deal of the month as it was taken private by Pamplona Capital Management. 3 July 2017
Pharmaceutical
The US Federal Trade Commission is currently accepting public comments on an application by Grifols, a Spain-based manufacturer of plasma-derived drugs, to amend the terms of a manufacturing agreement that was part of a 2011 FTC-ordered divestiture. 29 June 2017
Biosimilars
US biologics specialist Repligen has entered into a definitive merger agreement with privately-held Spectrum Inc. 28 June 2017
Generics
The proposed 5.3 billion euros ($5.9 billion), or 66 euros per share, acquisition of Stada Arzneimittel has failed to gain sufficient shareholder backing to proceed. 27 June 2017
Biotechnology
Cambridge, UK-based Innova Biosciences has been bought by Germany’s Sygnis Pharma, for up to 11.5 million euros ($13 million) in cash and shares. 26 June 2017
Generics
The Invent Farma/neuraxpharm, a group created by funds advised by private equity firm Apax Partners in August 2016, has made its first acquisition. 22 June 2017
Pharmaceutical
Pamplona Capital Management is to buy the USA-headquartered contract research organization (CRO) Parexel in a deal worth around $5 billion. 21 June 2017
Biotechnology
UK-government backed center the Cell and Gene Therapy Catapult (CGT Catapult) has sold off a subsidiary that has been developing and conducting Phase I/II clinical trials of a gene-modified T-cell therapy that actively targets several blood cancers and multiple solid tumors. 20 June 2017
Biotechnology
JSR Life Sciences, a division of Japan’s JSR Corporation, has agreed to acquire Selexis, a Switzerland-based privately-owned specialist in mammalian cell line development. 15 June 2017
Biotechnology
Australia’s CSL Limited saw its share close up 1.9% at A$137.65 today, after the company announced it has agreed to acquire an 80% equity stake of plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products (Ruide). 13 June 2017
Pharmaceutical
As part of the American Society of Clinical Oncology (ASCO) meeting, which overall was viewed as not particularly exciting this year, hitting the headlines was Roche’s presentation on Perjeta and Loxo Oncology’s much anticipated larotrectinib data. Elsewhere, there was positive data on AbbVie’s upadacitinib in rheumatoid arthritis, Valeant Pharmaceutical International shedding its Australian subsidiary iNovo, and Jazz Pharmaceuticals narcolepsy drug JZP-110. 11 June 2017
Biotechnology
US health care giant Johnson & Johnson says that, with today's receipt of approval of the proposed $30 billion acquisition of Swiss biotech firm Actelion from the European Commission (EC), all regulatory approvals required to complete the transaction have been received. 9 June 2017
Pharmaceutical
Troubled Canadian drugmaker Valeant Pharmaceuticals International has entered into an agreement to sell its iNova Pharmaceuticals business to a company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group for $930 million in cash. 8 June 2017
Pharmaceutical
SciClone Pharmaceuticals says it had entered into definitive merger agreement to be acquired by consortium of Chinese investors. 8 June 2017
Pharmaceutical
Ahead of the current and exciting news coming from ASCO over the weekend, hitting the headlines were Johnson & Johnson’s deal with Protagonist, Novartis setting out its future growth plans, small-cap French drugmaker Nicox gaining its first drug approval in the USA, GlaxoSmithKline filing for approval on a combination HIV treatment and Teva Pharmaceutical Industries’ progress with migraine drug candidate fremanezumab. 4 June 2017
Biotechnology
USA-based biopharma firm Sevion Therapeutics (OTCQB: SVON) announced on Friday that it has signed definitive agreement on May 31, 2017 for an acquisition transaction with Israel’s Eloxx Pharmaceuticals, a clinical-stage company developing therapeutics for genetic diseases caused by non-sense mutations. 3 June 2017
Pharmaceutical
While Thermo Fisher Scientific's $7.2 billion (NYSE: TMO) acquisition of Netherlands-incorporated CMO Patheon (NYSE: PTHN) was by far the biggest deal in the pharma and biotech space in May, it was not the only one. 2 June 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze